Garcinoic acid 是一种口服有效且能穿过血脑屏障的抗炎剂,可增强胞葬作用及酶/受体调节,靶向抑制人源 COX-2 (>10 μM)、猪源 α-淀粉酶 (IC50=28.91 μM)、酿酒酵母 α-葡萄糖苷酶 (IC50=41.08 μM) 及人源 DNA 聚合酶 β (IC50=11 μM),并激动人源 PXR,同时通过 MerTK、LRP-1 等受体增强巨噬细胞胞葬作用、促进促消退脂质介质生成、抑制 NF-κB 活化及促炎细胞因子分泌、干扰 Aβ 聚集、下调 NLRP3 炎症小体活性,并与 CD44、EGFR 等靶点结合以抑制白血病细胞增殖,其抗氧化、抗炎及调节脂质代谢等药理活性被广泛应用于动脉粥样硬化、阿尔茨海默病、2型糖尿病、炎症性肠病及病毒性肺炎等多种疾病的相关研究中。
产品编号: MS-O44115 CAS No.: 91893-83-3 分子式: C27H38O4 分子量: 426.59
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mg
询价
询价
25mg
询价
询价

产品描述

Garcinoic acid 是一种口服有效且能穿过血脑屏障的抗炎剂,可增强胞葬作用及酶/受体调节,靶向抑制人源 COX-2 (>10 μM)、猪源 α-淀粉酶 (IC50=28.91 μM)、酿酒酵母 α-葡萄糖苷酶 (IC50=41.08 μM) 及人源 DNA 聚合酶 β (IC50=11 μM),并激动人源 PXR,同时通过 MerTK、LRP-1 等受体增强巨噬细胞胞葬作用、促进促消退脂质介质生成、抑制 NF-κB 活化及促炎细胞因子分泌、干扰 Aβ 聚集、下调 NLRP3 炎症小体活性,并与 CD44、EGFR 等靶点结合以抑制白血病细胞增殖,其抗氧化、抗炎及调节脂质代谢等药理活性被广泛应用于动脉粥样硬化、阿尔茨海默病、2型糖尿病、炎症性肠病及病毒性肺炎等多种疾病的相关研究中。

生物实验数据

生物活性 Garcinoic acid is an orally active anti-inflammatory agent capable of crossing the blood-brain barrier that enhances efferocytosis and enzyme/receptor modulation, targets and inhibits human COX-2 (>10 μM), porcine α-amylase (IC50=28.91 μM), Saccharomyces cerevisiae α-glucosidase (IC50=41.08 μM), and human DNA polymerase β (IC50=11 μM), and agonizes human PXR, while enhancing macrophage efferocytosis through receptors such as MerTK and LRP-1, promoting the generation of pro-resolving lipid mediators, inhibiting NF-κB activation and pro-inflammatory cytokine secretion, interfering with Aβ aggregation, downregulating NLRP3 inflammasome activity, and binding to targets including CD44 and EGFR to suppress leukemia cell proliferation, with its pharmacological activities such as antioxidant, anti-inflammatory, and lipid metabolism-regulating effects being widely applied in research on various diseases including atherosclerosis, Alzheimer's disease, type 2 diabetes, inflammatory bowel disease, and viral pneumonia.
IC50 & Target

hCOX-2

 

体外研究
(In Vitro)

Garcinoic acid (2.5 μM; 24 h, 14-24 h) 可抑制 LPS 诱导的小鼠 RAW264.7 巨噬细胞中 Cox2 和 iNos 蛋白表达,在 2.5 μM 浓度下可将 iNos 水平降至 LPS 对照组的 17%。
Garcinoic acid 可抑制 KASUMI-1、HL-60、THP-1、RS4;11 和 MOLT-4 白血病细胞系的增殖,其 IC50 值范围为 18.04 μM 至 49.01 μM,对 HL-60 细胞的活性最强。
Garcinoic acid (0.25-5 μM; 24 h) 不会降低小鼠骨髓来源巨噬细胞的存活率。
外源性 Lipoxin A4 (100 nM; 2 h) 或 Resolvin E1 (10 nM; 30 min) 可恢复经 garcinoic acid (1 μM; 24 h) 处理后、Nrf2 沉默或 HO-1 抑制的小鼠骨髓来源巨噬细胞的胞葬作用增强效应。
Garcinoic acid (1-50 μM; 24 h) 可在 HepG2 细胞中呈剂量依赖性上调 PXR、CYP3A4 和 MDR1 的表达,且该响应依赖于具有功能活性的 PXR。
Garcinoic acid (25 μM; 24 h pre-incubation, 24 h incubation with Aβ(1-42)) 可通过不依赖 PPARγ 的机制恢复并刺激小鼠皮质星形胶质细胞中的 ApoE 外流,上调 PPARγ 和 PXR 的表达,并在 25 μM 浓度下增加这些细胞中受 PXR 调控的基因 CYP4F2 和 MDR1 的表达。
Garcinoic acid (5 μM; 6 h) 可在总孵育 6 小时后,抑制经 LPS/ATP 刺激的小鼠 J774A.1 巨噬细胞中 GSDMD 切割为诱导焦亡的 NT-GSDMD 片段。

Western Blot Analysis

Cell Line: murine RAW264.7 macrophages
Concentration: 2.5 μM
Incubation Time: 24 h (pre-incubated); 14 h (co-incubated with LPS for Cox2); 24 h (co-incubated with LPS for iNos)
Result: Did not detectably modulate basal Cox2 or iNos protein levels.
Reduced Cox2 protein expression to 67% relative to LPS-only controls.
Reduced iNos protein expression to 17% relative to LPS-only controls.

Cell Proliferation Assay

Cell Line: KASUMI-1, HL-60, THP-1, RS4;11, MOLT-4
Concentration: 0.02-100 μM
Incubation Time: 72 h (incubation with cells, following 24 h initial cell culture)
Result: Inhibited proliferation of KASUMI-1 cells, with an IC50 value of 30.81 μM.
Inhibited proliferation of HL-60 cells, with an IC50 value of 18.04 μM.
Inhibited proliferation of THP-1 cells, with an IC50 value of 49.01 μM.
Inhibited proliferation of RS4;11 cells, with an IC50 value of 42.87 μM.
Inhibited proliferation of MOLT-4 cells, with an IC50 value of 26.73 μM.

Cell Viability Assay

Cell Line: mouse bone marrow-derived macrophages (BMDMs)
Concentration: 0.25-5 μM
Incubation Time: 24 h
Result: Showed no cytotoxic effect on BMDMs, with cell viability remaining near 100% across all groups.
体内研究
(In Vivo)

Garcinoic acid (1 mg/kg;腹腔注射;每周 1 次;持续 8 周) 可显著降低高脂饮食喂养的 ApoE-/-小鼠的斑块内硝基酪氨酸水平,并调节部分全身及局部免疫细胞群,且不会改变动脉粥样硬化斑块大小或全身炎症介质水平。
Garcinoic acid (1 mg/kg;腹腔注射;每日;从 DSS 暴露前 7 天至研究结束) 可通过恢复胞葬作用、提升促消退特异性脂质介质水平及激活 Nrf2 信号通路,减轻雄性 C57BL/6 小鼠中 DSS (MS-A45736) 诱导的结肠炎。
Garcinoic acid (5-100 mg;口服;单次推注) 在小鼠体内作为选择性 PXR 激动剂,在≤25 mg 的耐受良好剂量下可剂量依赖性地升高肝脏和肠道组织中的 PXR、CYP3A11 和 MDR1 表达,而更高剂量会导致小鼠死亡。
Garcinoic acid (5-25 mg;口服;单剂量) 可剂量依赖性地上调健康 C57Bl/6 小鼠脑组织中的 PPARγ、ApoE 及 PXR 表达,当剂量≥5 mg 时可观察到显著效应。
Garcinoic acid (200 mg/kg;口服;每日一次;连续 10 天) 可显著减少 TgCRND8 阿尔茨海默病模型小鼠脑内 β 淀粉样蛋白斑块的数量与沉积,同时上调 ApoE 和 MDR1 的表达。

Animal Model: C57Bl/6 background (8-week-old male, 25-28 g, apolipoprotein E knockout, high fat diet-fed for 8 weeks)
Dosage: 1 mg/kg
Administration: i.p.; weekly; 8 weeks
Result: Decreased intra-plaque nitrotyrosine levels to 50% of control levels.
Downregulated blood CD4 positive T cells by 14.8%.
Increased blood natural killer (NK) cells from 3.2% to 5.6%.
Increased blood natural killer T (NKT) cells from 0.2% to 0.6%.
Upregulated spleen NK cells from 2.0% to 2.8%.
Showed no significant changes in body/organ weight, plasma lipid profile, total lesion size, necrotic core area, lipid content, collagen content, VCAM-1 levels, CD68 levels, MCP-1 levels, IL1β levels, plasma NO levels, or plasma prostanoid levels.
Animal Model: C57BL/6 (5-week-old male; DSS-induced colitis)
Dosage: 1 mg/kg
Administration: i.p.; daily; from 7 days pre-DSS exposure until study end
Result: Prevented DSS-induced reduction in colon length.
Increased body weight compared to DSS-only mice.
Reduced Disease Activity Index (DAI) scores compared to DSS-only mice.
Restored colonic tissue architecture, reducing epithelial degeneration, inflammatory cell infiltration, and crypt loss compared to DSS-only mice.
Increased the ratio of macrophage-associated apoptotic cells to free apoptotic cells in colon tissue, restoring efferocytosis to control levels.
Increased plasma levels of Lipoxin A4, Resolvin D2, and Resolvin E1 compared to DSS-only mice.
Increased colon tissue levels of Lipoxin A4, Resolvin D2, and Resolvin E1 compared to DSS-only mice.
Increased colon tissue protein levels of Nrf2 and NAD(P)H:quinone oxidoreductase (NQO1) compared to control mice.
Animal Model: TgCRND8 transgenic (5-month-old, 14-15-month-old)
Dosage: 200 mg/kg
Administration: p.o.; daily; 10 days
Result: Reduced 10-50 μm2 amyloid β plaques from ~400 to ~300, 50-200 μm2 plaques from ~100 to ~50, and 200-400 μm2 plaques from ~50 to ~10 (all significant vs. untreated Tg mice, p < 0.05 or p < 0.005) in 14-15-month-old Tg mice.
Confirmed decreased amyloid β deposition in both 5-month-old and 14-15-month-old Tg mice via Congo Red staining.
Increased ApoE and MDR1 expression in the hippocampus of Tg mice significantly.
Reached concentrations between 0.8 and 10.3 ppm (ng/mg of proteins) in the parietal cortex and hippocampus of treated Tg mice.

化学信息

分子量 426.59
分子式 C27H38O4
CAS No. 91893-83-3

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础